178 related articles for article (PubMed ID: 18155866)
1. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results.
Kuehl H; Antoch G; Stergar H; Veit-Haibach P; Rosenbaum-Krumme S; Vogt F; Frilling A; Barkhausen J; Bockisch A
Eur J Radiol; 2008 Aug; 67(2):362-371. PubMed ID: 18155866
[TBL] [Abstract][Full Text] [Related]
2. Early PET/CT after radiofrequency ablation in colorectal cancer liver metastases: is it useful?
Liu ZY; Chang ZH; Lu ZM; Guo QY
Chin Med J (Engl); 2010 Jul; 123(13):1690-4. PubMed ID: 20819630
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic performance of
Samim M; Molenaar IQ; Seesing MFJ; van Rossum PSN; van den Bosch MAAJ; Ruers TJM; Borel Rinkes IHM; van Hillegersberg R; Lam MGEH; Verkooijen HM
Surg Oncol; 2017 Mar; 26(1):37-45. PubMed ID: 28317583
[TBL] [Abstract][Full Text] [Related]
4. The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases.
Nielsen K; Scheffer HJ; Pieters IC; van Tilborg AA; van Waesberghe JH; Oprea-Lager DE; Meijerink MR; Kazemier G; Hoekstra OS; Schreurs HW; Sietses C; Meijer S; Comans EF; van den Tol PM
BMC Med Imaging; 2014 Aug; 14():27. PubMed ID: 25103913
[TBL] [Abstract][Full Text] [Related]
5. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results.
Veit P; Antoch G; Stergar H; Bockisch A; Forsting M; Kuehl H
Eur Radiol; 2006 Jan; 16(1):80-7. PubMed ID: 15868122
[TBL] [Abstract][Full Text] [Related]
6. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
7. Where there is no PET/CT.
Kuehl H; Antoch G; Bockisch A; Forsting M
Eur J Radiol; 2008 Aug; 67(2):372. PubMed ID: 18387765
[No Abstract] [Full Text] [Related]
8. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
[TBL] [Abstract][Full Text] [Related]
9. Where there is no PET/CT.
Ahmad MN; Zafar AM; Nadeem N
Eur J Radiol; 2009 Jun; 70(3):463-4. PubMed ID: 18387762
[TBL] [Abstract][Full Text] [Related]
10. Mid-term outcome of positron emission tomography/computed tomography-assisted radiofrequency ablation in primary and secondary liver tumours--a single-centre experience.
Kuehl H; Stattaus J; Hertel S; Hunold P; Kaiser G; Bockisch A; Forsting M
Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):234-40. PubMed ID: 18155453
[TBL] [Abstract][Full Text] [Related]
11. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
12. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT.
Vogt FM; Antoch G; Veit P; Freudenberg LS; Blechschmid N; Diersch O; Bockisch A; Barkhausen J; Kuehl H
J Nucl Med; 2007 Nov; 48(11):1836-44. PubMed ID: 17942811
[TBL] [Abstract][Full Text] [Related]
13. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
14. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases.
Donckier V; Van Laethem JL; Goldman S; Van Gansbeke D; Feron P; Ickx B; Wikler D; Gelin M
J Surg Oncol; 2003 Dec; 84(4):215-23. PubMed ID: 14756432
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of pattern classification 24 hours after radiofrequency ablation of liver metastases on CT and positron emission tomography/CT.
Vandenbroucke F; Vandemeulebroucke J; Ilsen B; Verdries D; Belsack D; Everaert H; Buls N; Ros PR; de Mey J
J Vasc Interv Radiol; 2014 Aug; 25(8):1240-9. PubMed ID: 24954606
[TBL] [Abstract][Full Text] [Related]
16. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation.
Rappeport ED; Loft A; Berthelsen AK; von der Recke P; Larsen PN; Mogensen AM; Wettergren A; Rasmussen A; Hillingsoe J; Kirkegaard P; Thomsen C
Acta Radiol; 2007 May; 48(4):369-78. PubMed ID: 17453514
[TBL] [Abstract][Full Text] [Related]
17. PET-CT after radiofrequency ablation of colorectal liver metastases: suggestions for timing and image interpretation.
Nielsen K; van Tilborg AA; Scheffer HJ; Meijerink MR; de Lange-de Klerk ES; Meijer S; Comans EF; van den Tol MP
Eur J Radiol; 2013 Dec; 82(12):2169-75. PubMed ID: 24021269
[TBL] [Abstract][Full Text] [Related]
18. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents.
Mainenti PP; Mancini M; Mainolfi C; Camera L; Maurea S; Manchia A; Tanga M; Persico F; Addeo P; D'Antonio D; Speranza A; Bucci L; Persico G; Pace L; Salvatore M
Abdom Imaging; 2010 Oct; 35(5):511-21. PubMed ID: 19562412
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
[TBL] [Abstract][Full Text] [Related]
20. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
